预约演示
Leo Pharma prepares to come for the topical JAK market as Incyte's Opzelura cream launch cools off
2024-05-03
临床3期上市批准临床结果
None
Watch out, Incyte. Leo Pharma and its JAK inhibitor cream delgocitinib are coming to disrupt the topical atopic dermatitis market, currently inhibited by Incyte’s approved Opzelura.
With severaIncytetiLeo Pharma in hand,JAK inhibitorJAKcluding a recent delgocitinibl pitting the candidate against theatopic dermatitis-of-care, Leo says its delgocitiIncytes growth driOpzelurantial.
Now, the drugmaker will be “investing additional resources in accelerating the launch of this potential treatment to patients,” Leo said in its fdelgocitinib earnings release.
The cream is currently under regulatory review in Europe. As for other markets including the U.S., Leo is “assessing ways” to bring the potential treatment to commercialization, it said.
Delgocitinib has been marked in Japan by Japan Tobacco for four years now.
Delgocitinibce supporting the drug includes two phase 3 studies against a placebo cream and an open-label extension study proving its success in treating patients with moderate-to-severe chronic hand eczema.
Most recently, delgocitinib went up against standard-of-care alitretinoin capsules, the only currently approved treatment for chronic hand eczema patients who do not respond to topical cochronic hand eczema
In the DELTA FOdelgocitinib 513 patients, Leo’s candidate proalitretinoinor reduction in scoring on the Hand Eczema Severity Ichronic hand eczema week 24. It also trumped alitretinoin in two other secondary measures assessing treatment success and quality of life.
“We are confident that with the DELTA FORCE study, delgocitinib cream may play a crucial role in expandiHand Eczemaons available for patients in this hard-to-treat conditialitretinoinevelopment officer Kreesten Meldgaard Madsen said at the time.
If the drug scores approval, it would compete with delgocitiniber marketed topical JAK inhibitor, Incyte’s Opzelura.
That med is a cream version of the company’s popular JAK inhibitor Jakafi. Other thJAK inhibitorJAKatopic dermaIncyte OpOpzeluras also approved to treat vitiligo.
Incyte is now moving to expand the Jakafi counterpartJAK inhibitorJAKto pediatriJakafiic dermatitisatopic dermatitistoOpzeluraits bid for the indication vitiligor along with “multiple data readouts,” head of R&D Pablo Cagnoni said on the company’s first-quarter earnings call. A pediatric nod would add some two million to three million eligible patients to the med’s reach, the company said.
Incytera and Jakafi brought Incyte Jakafickbuster fourth-qupediatric atopic dermatitisecting what the company’s North America general manager Barry Flannelly called “one of the best recent dermatology launches” on Opzelura’s part following its 2021 approval.
More recently over this yearIncytest quarter, sales for both Opzelura and Jakafi sank on a quarterly basis, missing analyst’s consensus.
Opzelura pulled first-quarter revenues of $86 million, dipping 21.5% from the fourth quarter.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
靶点
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。